Circulating membrane microparticles in women with arterial hypertension and neurocirculatory dystonia
Circulating membrane microparticles in blood are known as new marker of endothelium dysfunction and progression of cardiovascular diseases. Objective: to study the dynamics of circulating membrane microparticles in blood of patients with arterial hypertension (AH) or neurocirculatory dystonia (NCD) combined type at the time of treatment with trimetazidine. Methods: the study included patients 30-50 years old with AH stage II-III or NCD (n = 162). Cholesterol and coagulation factors levels were tested. Patients were allocating to trimetazidine group (70 mg daily during 30 days) and control group treated according to typical practice. Results: women with AH stage III and increased levels of cholesterol and coagulation factors had high level of membrane microparticles (178.0 ± 8.7 units in 4 cm2 of blood sample) compared to patients with hypercoagulation but with normal level of cholesterol (140.2 ± 9.2 units; p < 0.001), to those who had increased level of cholesterol without hypercoagulation (80.3 ± 10.2 units; p < 0.01) and to healthy women (7.5 ± 7.7 units; p < 0.001). Patients with AH stage II had no significant differences between subgroups with different levels of cholesterol and coagulation factors. The level of circulating membrane microparticles was higher in women with NCD (68.4 ± 2.8 units) than in healthy women (p < 0.05). Treatment with trimetazidine resulted in significant decrease of number of circulating membrane microparticles. Conclusion: circulating membrane microparticles are able to be the marker of pathological lesions in cardiovascular system. Trimetazidine is efficient for the decrease if their concentration in patients with AH and NCD.